机器人辅助根治性前列腺癌术后功能恢复与肿瘤结局:后入路与标准前入路的随机对照比较
该随机对照试验纳入120例临床低中危前列腺癌患者,比较后入路(Retzius保留)与前入路机器人辅助根治性前列腺癌术后1年功能恢复、肿瘤结局及并发症。结果显示两组在尿控率、勃起功能及生化复发无显著差异,后入路组非局灶切缘阳性率、生化无复发生存概率及并发症发生率数值上略差但未报告统计学比较。
要点
- 术后12个月,前入路组尿控率93.3% vs 后入路组98.3%,无统计学显著差异(p=0.09)。
- 两组术后12个月勃起足以性交比例及SHIM评分≥17比例无显著差异。
- 后入路组非局灶切缘阳性率11.7% vs 前入路组8.3%,生化无复发生存概率0.84 vs 0.93。
核心结论
- 在临床低中危前列腺癌患者中,前入路与后入路机器人辅助根治性前列腺癌术后12个月尿控差异较3个月时减弱,性功能恢复、并发症及生化复发率相当。
研究设计与样本
- 随机对照试验,纳入120例临床低中危前列腺癌患者,后入路与前入路各60例,由单一学术机构单一手术团队完成手术,独立第三方评估术前及术后3、6、12个月尿路与性功能。
主要发现
- 术后12个月,前入路组 vs 后入路组尿控率(每日0-1片安全垫)93.3% vs 98.3%(p=0.09),24小时尿垫重量中位数12 gm vs 7.5 gm(p=0.3)。
- 术后12个月,前入路组 vs 后入路组勃起足以性交69.2% vs 86.5%,术后SHIM评分≥17比例44.6% vs 44.1%。
- 后入路组 vs 前入路组非局灶切缘阳性率11.7% vs 8.3%,生化无复发生存概率0.84 vs 0.93,术后并发症发生率18.3% vs 11.7%。
关键数值与推荐
- 生化复发定义为术后2次前列腺特异性抗原(PSA)≥0.2 ng/ml。
- 尿控定义:每日0-1片安全垫。
- 中位年龄61岁,中位随访12个月。
临床怎么用
- 对于临床低中危前列腺癌患者,前入路与后入路机器人辅助根治性前列腺癌术后1年尿控、性功能恢复、并发症及生化复发率无显著差异。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We report a 1-year update of functional urinary and sexual recovery, oncologic outcomes and postoperative complications in patients who completed a randomized controlled trial comparing posterior (Retzius sparing) with anterior robot-assisted radical prostatectomy. MATERIALS AND METHODS: A total of 120 patients with clinically low-intermediate risk prostate cancer were randomized to undergo robot-assisted radical prostatectomy via the posterior and anterior approach in 60 each. Surgery was performed by a single surgical team at an academic institution. An independent third party ascertained urinary and sexual function outcomes preoperatively, and 3, 6 and 12 months after surgery. Oncologic outcomes consisted of positive surgical margins and biochemical recurrence-free survival. Biochemical recurrence was defined as 2 postoperative prostate specific antigen values of 0.2 ng/ml or greater. RESULTS: Median age of the cohort was 61 years and median followup was 12 months. At 12 months in the anterior vs posterior prostatectomy groups there were no statistically significant differences in the urinary continence rate (0 to 1 security pad per day in 93.3% vs 98.3%, p = 0.09), 24-hour pad weight (median 12 vs 7.5 gm, p = 0.3), erection sufficient for intercourse (69.2% vs 86.5%) or postoperative Sexual Health Inventory for Men score 17 or greater (44.6% vs 44.1%). In the posterior vs anterior prostatectomy groups a nonfocal positive surgical margin was found in 11.7% vs 8.3%, biochemical recurrence-free survival probability was 0.84 vs 0.93 and postoperative complications developed in 18.3% vs 11.7%. CONCLUSIONS: Among patients with clinically low-intermediate risk prostate cancer randomized to anterior (Menon) or posterior (Bocciardi) approach robot-assisted radical prostatectomy the differences in urinary continence seen at 3 months were muted at the 12-month followup. Sexual function recovery, postoperative complication and biochemical recurrence rates were comparable 1 year postoperatively.
引用
- Menon M, Dalela D, Jamil M, et al. Functional Recovery, Oncologic Outcomes and Postoperative Complications after Robot-Assisted Radical Prostatectomy: An Evidence-Based Analysis Comparing the Retzius Sparing and Standard Approaches. J Urol. 2017. PMID: 29225060. doi:10.1016/j.juro.2017.11.115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。